# A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

> **NCT01937715** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Colorectal Carcinoma

## Interventions

- **DRUG:** PF-05212384
- **DRUG:** FOLFIRI regimen
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT01937715
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction
- **Last updated:** 2016-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937715, "A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01937715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*